N-acetylcysteine administration in treatment of metabolic syndrome

Comparing the effects of N-acetylcysteine and placebo on metabolic profiles and serum adiponectin levels in patients with metabolic syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N72

Enrollment

Registered

2020-06-23

Start date

2020-06-28

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group: N-acetylcysteine 600 mg Tablet (Osve Pharmaceutical Co., Tehran, Iran), orally, three times a day, for 12 weeks. Intervention 2: Control group: Placebo Tablet (Osve

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with metabolic syndrome Individuals aged 25-75 years old

Exclusion criteria

Exclusion criteria: Patients with infectious, malignant and inflammatory diseases Those taking any antioxidant and/or anti-inflammatory supplements within 16 weeks prior to enrollment in the study Hypersensitivity to the study medication Pregnancy or breastfeeding Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using the Homeostasis Model Assessment (HOMA) formula.	—

Secondary

Measure	Time frame
Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Low-density lipoprotein (LDL). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Adiponectin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.	—

Measure

Time frame

Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Low-density lipoprotein (LDL). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Adiponectin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Yunes Panahi

Bagheiat-allah University of Medical Sciences

yunespanahi@yahoo.com+98 21 8804 0060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026